Abstract

Hypopharyngeal squamous cell carcinoma (HSCC) has the worst prognosis among head and neck cancers. Cisplatin (DDP)-based chemotherapy is an important part of multimodal treatments. However, resistance to DDP severely impairs the effectiveness of chemotherapy for HSCC. Chloroquine (CQ) has been reported to enhance the effectiveness of chemotherapy and radiotherapy in liver, pancreas, breast, prostate and colon tumors, but it is unclear whether CQ could increase the efficacy of DDP for treating HSCC. We inoculated BALB/c nude mice with a subcutaneous injection of human hypopharyngeal FaDu cells to generate our animal model. Mice were randomly divided into 4 groups and treated with vehicle control, CQ (60 mg/kg/day), DDP (5 mg/kg/6 days), or a combination of DDP and CQ. Tumor growth and survival of the mice were monitored. We found that CQ inhibited autophagy and increased DDP-induced apoptosis in the xenograft mouse model. CQ enhanced the efficacy of DDP, resulting in decreased tumor growth and prolonged survival of the mice. To test whether blocking autophagy enhanced the efficacy of DDP, FaDu cells were infected with lentiviral shRNA to Beclin-1 and inoculated into the flanks of nude mice. Inhibition of autophagy markedly enhanced the DDP-induced antitumor effect. Our study suggests that the addition of CQ to DDP-based chemotherapy could be a potential therapeutic strategy for treating HSCC, and the inhibition of autophagy may contribute to chemotherapy sensitization in HSCC.

Highlights

  • Hypopharyngeal squamous cell carcinoma (HSCC) accounts for approximately 3 to 5% of all head and neck cancers

  • We reported that the levels of Beclin-1 and light chain 3 (LC3) were downregulated in human HSCC [28], indicating an altered autophagy level in hypopharyngeal cancer cells

  • We reported that levels of Beclin-1 and LC3 were downregulated in the human HSCC tissues and low expression of beclin-1 and LC3 could correlate with poor prognosis for patients [28]

Read more

Summary

Introduction

Hypopharyngeal squamous cell carcinoma (HSCC) accounts for approximately 3 to 5% of all head and neck cancers. The prognosis of HSCC is very poor, and the 5-year overall survival rate is approximately 15 to 45% [1,2,3]. Cisplatin (DDP)-based chemotherapy is an important part of the multimodality treatment for head and neck cancers [4,5]. Intrinsic and acquired resistance to DDP is common in HSCC treatment, and the effectiveness of chemotherapy is PLOS ONE | DOI:10.1371/journal.pone.0126147. Chloroquine in Treatment of Hypopharyngeal Carcinoma often severely compromised [6]. It has remained difficult to effectively overcome DDP resistance in chemotherapy for head and neck cancers

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.